Compare DOX & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOX | LQDA |
|---|---|---|
| Founded | 1982 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 5.5B |
| IPO Year | 1998 | 2020 |
| Metric | DOX | LQDA |
|---|---|---|
| Price | $58.55 | $89.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | ★ $92.33 | $41.00 |
| AVG Volume (30 Days) | ★ 1.3M | 1.3M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.56% | N/A |
| EPS Growth | N/A | ★ 51.81 |
| EPS | N/A | ★ 0.52 |
| Revenue | N/A | ★ $158,320,000.00 |
| Revenue This Year | $4.48 | $278.87 |
| Revenue Next Year | $3.76 | $57.13 |
| P/E Ratio | ★ $13.65 | $171.96 |
| Revenue Growth | N/A | ★ 1031.18 |
| 52 Week Low | $49.74 | $19.90 |
| 52 Week High | $90.29 | $91.57 |
| Indicator | DOX | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 64.94 | 63.70 |
| Support Level | $49.81 | $31.99 |
| Resistance Level | $64.77 | $91.10 |
| Average True Range (ATR) | 1.87 | 5.03 |
| MACD | 0.72 | -0.02 |
| Stochastic Oscillator | 91.16 | 85.26 |
Amdocs Ltd is a provider of software and services to communications, entertainment, and media service providers. The Company operates in a single segment and designs, develops, markets, supports, implements, and operates open and modular cloud offerings. Its portfolio includes solutions across digital business systems and legacy business and operational support systems, supporting multiple lines of business such as wireless, broadband, cable, fiber, satellite, and digital services. The Company leverages artificial intelligence to support digital transformation, cloud adoption, and intelligent network automation. Geographically, it derives a majority of its revenue from North America and also operates in Europe and the rest of the world.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.